Biohacker Slams AG1: 'No Clinical Benefit!'

Biohacker Bryan Johnson has publicly questioned the efficacy of the popular AG1 supplement, asserting it provides no clinical benefits. Johnson, known for his extensive daily supplement regimen, pointed to a 2024 clinical trial involving 30 adults. This study revealed minor improvements in the gut microbiome for AG1 users but found these changes were not statistically significant when compared to a placebo group.

Johnson suggests consumers opt for more cost-effective gut health solutions such as chicory inulin and resistant starch. These alternatives are considerably less expensive than AG1's monthly subscription cost of $79. The brand AG1 responded to Johnson's claims, stating that the referenced study does not accurately represent their findings and that multiple trials demonstrate positive impacts.

The 2024 trial, published in the Journal of the International Society of Sports Nutrition, explored AG1's effects on gut bacteria and digestive health. While it found AG1 to be safe for daily consumption, the improvements were not significant enough to draw firm conclusions without further research, particularly in individuals with gastrointestinal issues.

Chicory inulin and resistant starch, while associated with potential benefits like improved digestion and blood sugar control, also have limited study data and can cause digestive discomfort in higher doses. The debate highlights differing perspectives on the value of popular supplements versus more traditional or research-backed alternatives.